SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Human & Experimental Toxicology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Jefferys, D.B.
Right arrow Articles by Volans, G.N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Jefferys, D.B.
Right arrow Articles by Volans, G.N.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

An Investigation of the Role of the Specific Opioid Antagonist Naloxone in Clinical Toxicology

D.B. Jefferys

Poisons Unit, Guy's Hospital, London SE1 9RT

G.N. Volans

Poisons Unit, Guy's Hospital, London SE1 9RT

1 An assessment of the current role of naloxone in clinical toxicology has been made in a series of three separate epidemiological studies.

2 Through the National Poisons Information Service we found that the role of naloxone in opioid poisoning is often not appreciated by the enquirer and that toxicological screening is often requested before the diagnostic use of naloxone.

3 The recommended dose of naloxone (0.4-1.2 mg i.v.) is not always adequate. In 51 cases where naloxone was effective, doses of up to 3.2 mg were necessary (mean 1.8 ± 0.3 mg SEM i.v.).

4 In 31 cases of non-opioid poisoning, naloxone in doses of 0.4-1.2 mg i.v. caused no deterioration, whilst six patients in whom no opioids were detected showed clinical improvement.

5 In 300 cases of suspected ethanol-induced coma, 49 showed reversal of coma with naloxone, and in 38 cases ethanol was the sole cause of coma (mean plasma concentration 3.54 ± 0.62 g/l SEM).

6 These results suggest that the role of naloxone in clinical toxicology is not fully appreciated. There is a need for further education as to its indications in opioid poisoning, together with additional studies to define more accurately the dose/response relationship. In addition, the role of naloxone in coma induced by ethanol and certain other non-opioids needs to be evaluated further.

Human & Experimental Toxicology, Vol. 2, No. 2, 227-231 (1983)
DOI: 10.1177/096032718300200209


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement